Susan J Done

Susan J Done, MBA, PhD, MB Bchir, MB, FRCPC

In our lab the primary focus is the identification and characterization of molecular alterations that lead to the development of solid cancers, particularly breast cancer. It is believed that the study of these changes will lead to the identification of potential diagnostic, prognostic and predictive markers and also therapeutic targets.

Cancer results from a progressive accumulation of genetic alterations. In some organ systems (eg, colon, cervix) it has been demonstrated that these increasing degrees of genetic perturbation are accompanied by increasing degrees of histologic dysplasia. Other tissues are less accessible making the establishment of these links more difficult.

In the breast, certain preneoplastic and preinvasive lesions (hyperplasias and ductal carcinoma in situ) have been linked to invasive breast cancer by the increased relative risk of future invasive disease they confer. However, it has not been clearly established whether these lesions have the potential to progress to invasive breast cancer or are merely markers of increased risk. Advances in tissue microdissection and PCR technologies have made possible the study of molecular alterations in these small, histologically defined lesions.

We believe it is important to localize particular genetic aberrations to specific cells thereby enabling a correlation between histologic and genetic changes. This correlation is effected using advanced molecular techniques in several ways: firstly, tissue microdissection involving laser capture microdissection can be used in some cases; and secondly, fluorescence in situ hybridization (FISH) analysis can allow detection of gene copy number in specific cells.

Current projects in the lab involve the use of gene microarray chips to identify genes and chromosomal regions that are amplified or deleted in the transition from preinvasive to invasive breast cancer and determination of the extent of genomic instability in histologically normal tissue adjacent to invasive carcinoma.

Related Links

Breast. 2017 Aug 03;:
Rakovitch E, Nofech-Mozes S, Hanna W, Sutradhar R, Gu S, Fong C, Tuck A, Youngson B, Miller N, Done SJ, Chang MC, Sengupta S, Elavathil L, Jani PA, Bonin M, Lalani N, Paszat L
Biomed Opt Express. 2016 Oct 1;7(10):4054-4068
Golaraei A, Kontenis L, Cisek R, Tokarz D, Done SJ, Wilson BC, Barzda V
Int J Mol Sci. 2016;17(9)
Lowes LE, Bratman SV, Dittamore R, Done S, Kelley SO, Mai S, Morin RD, Wyatt AW, Allan AL
Breast Cancer Res Treat. 2015 Oct 30;
Chiarelli AM, Prummel MV, Muradali D, Shumak RS, Majpruz V, Brown P, Jiang H, Done SJ, Yaffe MJ
Cancer Res. 2015 Sep 23;
Wright KL, Adams JR, Liu JC, Loch AJ, Wong RG, Jo CE, Beck LA, Santhanam DR, Weiss L, Mei X, Lane TF, Koralov SB, Done SJ, Woodgett JR, Zacksenhaus E, Hu P, Egan SE
Radiology. 2015 Sep 2;:150733
Prummel MV, Muradali D, Shumak R, Majpruz V, Brown P, Jiang H, Done SJ, Yaffe MJ, Chiarelli AM
Springerplus. 2015;4:335
Klein J, Kong I, Paszat L, Nofech-Mozes S, Hanna W, Thiruchelvam D, Narod SA, Saskin R, Done SJ, Miller N, Youngson B, Tuck A, Sengupta S, Elavathil L, Jani PA, Slodkowska E, Bonin M, Rakovitch E
J Clin Oncol. 2015 May 11;
Liu FF, Shi W, Done SJ, Miller N, Pintilie M, Voduc D, Nielsen TO, Nofech-Mozes S, Chang MC, Whelan TJ, Weir LM, Olivotto IA, McCready DR, Fyles AW

Pages


 

Associate Professor, Departments of Medical Biophysics and Laboratory Medicine & Pathobiology, University of Toronto